All In Biotech

NDA 204200 · Ph Health

Adrenalin

Epinephrine · Intramuscular, Intravenous, Subcutaneous · alpha-Adrenergic Agonist; beta-Adrenergic Agonist; Catecholamine

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Dec 7, 2012

Approved uses

3

Original approval plus efficacy supplements

Registered trials

2,347

454 Phase 3, 232 recruiting

FAERS reports

42,905

26,807 serious, 3,624 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 22, 2026.

1.1 Anaphylaxis Emergency treatment of allergic reactions (Type I), including anaphylaxis, which may result from insect stings or bites, foods, drugs, sera, diagnostic testing substances and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. 1.2 Hypotension associated with Septic Shock Adrenalin is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. Adrenalin® is a non-selective alpha and beta adrenergic agonist indicated for: Emergency treatment of allergic reactions (Type 1), including anaphylaxis (1.1) To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock (1.2)

Therapeutic areas: Kidney and urology · Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 29, 2019 Supplement 9 · Efficacy LabelLetter
  • Dec 7, 2012 Original approval · Type 7 - Drug Already Marketed without Approved NDA LabelReviewSummary Review
  • Dec 7, 2012 Original approval · Efficacy · priority review
1 products under this application
  • ADRENALIN · EPINEPHRINE EQ 1MG BASE/ML (EQ 1MG BASE/ML) · SOLUTION, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Epinephrine" as an intervention, any sponsor and status, largest first.

All 2,347 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,582
  • headache3,085
  • sinusitis2,921
  • fatigue2,812
  • product dose omission issue2,782
  • pain2,498
  • covid-192,425
  • dyspnoea2,298
  • nausea2,239
  • off label use2,136
  • pneumonia2,081
  • inappropriate schedule of product administration1,786

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004135
2005118
2006136
2007166
2008194
2009275
2010267
2011706
2012431
2013342
2014444
2015673
20161,133
20171,654
20182,514
20193,369
20206,479
20213,953
20223,610
20233,814
20244,459
20254,763
20263,267

Recalls

3 FDA enforcement reports for this application.

  • Jan 17, 2024 · Class II · Completed

    Labeling: Incorrect or Missing Lot and/or Exp Date. The expiration date listed on the Repack Pouch Label is incorrect.

  • Mar 16, 2023 · Class III · Ongoing

    Labeling; Incorrect NDC number on outer carton of product.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Adrenalin (Epinephrine)

2024 spending

$61K

Beneficiaries

2,713

2,931 claims

Per beneficiary

$22

$13.74 per unit

View as table
YearSpending
2020$16,833
2021$27,653
2022$39,447
2023$50,592
2024$60,692

Part B: Adrenalin* (Epinephrine*) · HCPCS J0171

2024 spending

$11K

Beneficiaries

2,258

2,659 claims

Per beneficiary

$5

2024 ASP limit $0.80 per unit

View as table
YearSpending
2020$13,826
2021$9,133
2022$11,648
2023$10,137
2024$11,180

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,632 on PubMed

Sponsor: Ph Health

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.